Phaseline

Targets › CD84

CD84 (SLAM family member 5): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout May 2029.

Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. (UniProt, Q9UIB8)

Open in Phaseline: the race on CD84, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Gyala TherapeuticsGYA01 (CART84)
anti-CD84 chimeric antigen receptor (CAR) T-cell therapy
CD84Phase 1Acute Myeloblastic LeukaemiaMay 2029

Conditions

Acute Myeloblastic Leukaemia (1)

Modalities

small molecule (1)

Companies

Gyala Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.